The company completed a clinical trial at nine centers across the U.S., Europe and Asia before it received FDA approval.

New research shows that inhibiting overactive LRRK2 enzymes could stabilize Parkinson's disease progression, with Stanford ...

Dr. Simrit Parmar, a Northwestern University-trained oncologist and research scientist, launched Cellenkos Inc., in 2016 to ...

A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, ...

The findings of two recent studies give hope that the disease could one day be reversed in humans—but experts warn that this ...

A drug used for Parkinson's disease has been shown to be effective in reducing the symptoms of difficult to treat depression, ...

The results of experiments in mice models were "astounding," said biochemist Suzanne Pfeffer of Stanford University.

Currently dopamine replacement medications, like levodopa and dopamine agonists, are the primary treatment for Parkinson's ...

When 64-year-old MBK Nair first noticed a subtle tremor in his right hand in 2020, he brushed it off as fatigue or muscle weakness, assuming that could be a sig ...

Parkinson's disease is a neurogenerative disease that affects more than 1 million people in the U.S. While some cases are ...

Most Parkinson's symptoms stem from the loss or dysfunction of dopamine-producing neurons in a brain region involved in fine ...

Epworth Geelong has become the first hospital outside Melbourne to offer deep brain stimulation, giving Western Victorians with Parkinson's disease ...